Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRG-001 in Alcoholic Hepatitis
NCT06307522Phase 2
Key facts
- Status
- Not yet recruiting
- Start
- Sep 2024
- Primary completion
- Sep 2026
- Sponsor
- MedRegen LLC
- Modality
- Small Molecules
- Drugs
- MRG-001
- Conditions
- alcoholic hepatitis (AH)
01
Overview
Phase 2, open-label trial of MRG-001 in alcoholic hepatitis (AH) (3 arms), sponsored by MedRegen LLC. Primary endpoint: Assessment of Treatment-Emergent Adverse Events at 28 Days. Planned start Sep 2024; status: not yet recruiting.
02
Design
3 arms- Study design
- Non-randomizedOpen-label
MRG-001 (0.005 mL/kg)
Lowest dose
MRG-001 (0.007 mL/kg)
Intermediate dose
MRG-001 (0.01 mL/kg)
High dose
03
Endpoints
Primary
Assessment of Treatment-Emergent Adverse Events
Secondary
Pharmacokinetic Response
Pharmacodynamic Response
Beyond the preview
Go deeper on NCT06307522.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06307522.